The 7-Step Eye Cream Sourcing Checklist I Wish I'd Had on My First Order

I've been placing eye cream sourcing orders for about six years. Roughly 180 POs, mostly in the 500–20,000 unit range. Along the way I've made five mistakes large enough that my manager still brings them up — call it $4,200 in write-offs, rework, and one delayed launch I'd rather forget.

This is the checklist I use now, in order. Seven steps. It works the same whether the line is eye cream for wrinkles, brightening eye cream, an eye cream for bags (that's the search term every brand cares about — the actual concern is puffiness and the appearance of shadowing), eye cream for sensitive skin, or just a plain hydrating eye cream.

If you're a buyer doing eye cream sourcing for a private label or distributor, this is the sequence. If you're manufacturing in-house or working at 100k+ unit scale, some of it will apply less directly.

Step 1: Turn the category keyword into an actual formula map

"Anti-wrinkle eye cream" is a listing title, not a spec. Two suppliers can quote the same keyword and send you formulas with almost nothing in common.

What I ask for now, before any pricing conversation: a one-page formula storyboard. Active ingredient, function (occlusive, humectant, peptide, vitamin C derivative, caffeine, whatever), target feel, and the regulatory category the supplier thinks it falls into. For a brightening eye cream, I want to know which component is doing the actual brightening job and at what percent. For a hydrating eye cream, I want the humectant stack laid out — the ones that list only glycerin tend to under-deliver once the formula hits a 12-month stability test.

The supplier's spec sheet is usually described as "flexible." What I mean by that is they'll move percentages if you push hard enough, which tells you the original spec wasn't really a spec.

Checkpoint: if the supplier can't send the storyboard within 48 hours, they either don't have it documented or don't want you to see it. Both are answers.

Step 2: Treat the INCI list and the COA as two separate documents

I once approved a 3,000-unit order on a COA that came stapled to the INCI table. They looked consistent. They weren't — the COA was for a different batch run than the one that shipped. That cost around $700 to sort out in third-party testing plus a two-week delay.

Now they're separate files on my desk. The INCI list gets checked against what the label claims (INCI names are standardized; I use the Personal Care Products Council naming reference). The COA gets checked for batch number, test date, microbial results, heavy metals, and shelf-life start date. The batch number on the COA has to match the batch number on the shipping docs. If those two don't line up, stop.

Step 3: Run a patch panel before you sign off on "for sensitive skin"

Every sensitive skin eye cream claims to be tested for sensitive skin. The claim in the brochure is not the test method. I want the actual method — panel size, duration, application site (upper cheek vs orbital area vs lower lid), scoring rubric, and what "no irritation reported" means numerically.

The pitch is usually "great for sensitive skin." What that often actually means is "no added fragrance" — which is a good thing to have, but not the same claim.

My rule is a 20–30 person internal panel, patch-tested on the upper outer orbital area for 48 hours, plus a follow-up at 7 days. If the supplier won't provide their method, I run my own anyway. It's cheap next to a rework.

(And yes, every eye cream is "hydrating." That word costs nothing to print.)

Step 4: Build the TCO per category, not the unit price

Here's where I've made the most expensive mistake of my career. Twice.

Unit price feels like the number to compare. It isn't. The number that matters is total landed cost per sellable unit, and that has a lot of moving pieces:

• Unit price
• Dead stock from MOQ overshoot (how many units will sit in a warehouse past shelf life?)
• Third-party testing per batch (micro, stability, sometimes heavy metals)
• Label revision fees if INCI formatting doesn't pass regulatory review
• Shipping mode (sea vs air vs courier — the spread on small orders is brutal)
• Rework or scrap risk on first-year suppliers
• Delay cost if the launch slips

A vendor quoting $1.20/unit at 10,000 MOQ with sea freight may lose badly to a vendor quoting $1.55/unit at 2,500 MOQ with courier included — by the time you add dead stock, label rewinds, and slip risk. I've watched that exact scenario play out. The $1.55 quote was the cheaper option by a meaningful margin once I built the actual TCO.

I don't have a clean formula for delay cost, and I won't pretend I do. Roughly speaking, for our business, a two-week slip on an eye cream launch is worth about $1,500–2,500 in lost promo slots. Try not to hold me to that number — my sense of it comes from two slip events, not from any benchmark data set.

Step 5: Check packaging compatibility before you lock the formula

Eye cream travels in a lot of formats — jar, tube, airless pump, rollerball, ceramic dropper. Every one of them can shift the stability profile of a formula that tested clean in the lab's default container.

Ask the supplier to confirm the formula was stability-tested in the exact container their quote is for. If they tested in a jar and quoted a tube, the 12-month stability data doesn't transfer. This is the step most buyers skip, and it's the one that bites hardest on the second order, not the first.

Step 6: Confirm traceability and regulatory documents

For any eye cream sourcing program, I want, at minimum: ISO 22716 GMP certification (or the equivalent for the supplier's jurisdiction), a mutually agreed batch traceability process, and the regulatory framework the formula is filed under. In the EU, that means CPNP notification under Regulation (EC) No 1223/2009. In the US, cosmetic labeling and claim substantiation follow FDA rules — with the caveat that anti-wrinkle and eye-bag language has to stay inside cosmetic claim territory, not drug territory. If a label says "treats wrinkles" or "cures eye bags," that's a regulatory red flag, not a marketing win.

I'm not a regulatory consultant, and I say so openly to my team. Anything borderline routes through an actual reviewer.

Step 7: Run a small batch before committing to volume

The first order is a test, even when the MOQ forces you into a batch that's larger than you want. My rule is: order the smallest batch the supplier will accept, approve it on arrival, and hold the full-volume PO until that batch has been in market for 30 days with no quality issues reported.

The only exception is when time pressure forces your hand — and it will. In July 2023 I had three hours to approve a re-order of a brightening eye cream before a sales deadline. Normally I'd run a full pre-check. That day I went on trust. The INCI label formatting had drifted on a minor update, nobody caught it on the supplier side, and we spent two days issuing corrected stickers on 400 units. Nothing catastrophic. Just avoidable.

What still catches people — including me

A few things that aren't covered by any one step:

• "Sensitive skin safe" as a brochure claim. Always ask for the test method, not the claim. If they can't produce a method write-up, treat the claim as marketing.
• First-tier suppliers who are actually brokers. If the COA comes from a different company name than the one on the invoice, you're talking to a trader, and you don't have traceability.
• MOQ pricing that assumes one run per year. If the shelf life on a jar of eye cream is 36 months and you sell 1,200 units a year, a 10,000 MOQ buy is 6+ years of inventory. That's not a cheap price — it's an inventory problem you haven't felt yet.
• Shipping quotes that exclude last-mile fees. The quote-to-invoice gap on small eye cream orders is routinely 15–25% once import clearance and final delivery step in.

None of this is exotic. It's just the stuff that's easier to skip when the timeline is tight. Which is exactly when it gets skipped.